Literature DB >> 31307893

Hyperpolarized MR - What's up Doc?

Jan H Ardenkjaer-Larsen1.   

Abstract

Hyperpolarized MR by dissolution Dynamic Nuclear Polarization (dDNP) appeared on the scene in 2003. Since then, it has been translated to the clinic and several sites are now conducting human studies. This has happened at record pace despite all its complexities. The method has reached a pivotal point, and the coming years will be critical in realizing its full potential. Though the field has been characterized by strong collaboration between academia, government and industry, the key message of this perspective paper is that accelerated consensus building is of the essence in fulfilling the original vision for the method and ensuring widespread adoption. The challenge is to gain acceptance among clinicians based on strong indications and clear evidence. The future appears bright; initial clinical data looks promising and the scope for improvement is significant.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dissolution-DNP; Hyperpolarization; Hyperpolarized MR

Year:  2019        PMID: 31307893     DOI: 10.1016/j.jmr.2019.07.017

Source DB:  PubMed          Journal:  J Magn Reson        ISSN: 1090-7807            Impact factor:   2.229


  3 in total

1.  Overhauser dynamic nuclear polarization (ODNP)-enhanced two-dimensional proton NMR spectroscopy at low magnetic fields.

Authors:  Timothy J Keller; Thorsten Maly
Journal:  Magn Reson (Gott)       Date:  2021-04-12

2.  Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience.

Authors:  Shuyu Tang; Maxwell V Meng; James B Slater; Jeremy W Gordon; Daniel B Vigneron; Bradley A Stohr; Peder E Z Larson; Zhen Jane Wang
Journal:  Cancer       Date:  2021-04-12       Impact factor: 6.860

Review 3.  Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly.

Authors:  Adam Retter; Fiona Gong; Tom Syer; Saurabh Singh; Sola Adeleke; Shonit Punwani
Journal:  Mol Oncol       Date:  2021-08-30       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.